This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Shigella and enterotoxigenic Escherichia coli (ETEC) are two of the most important causes of disease and death caused by diarrhea among infants and children living in poor countries of Asia and Africa. Soldiers and other travelers to these areas of the world can also become ill from these infections. Shigella and ETEC are spread by direct contact with people who have these infections and do not wash their hands well after using the toilet or by unclean food and water. As a result, it is hard to stop the spread of these infections in places where hygiene and sanitation are not good. In addition, antibiotics that worked well in the past can no longer cure some Shigella and ETEC infections. For these reasons, vaccines are being developed and tested for their ability to prevent diarrheal disease due to Shigella and ETEC. The experimental vaccine given in this study is made from an illness-causing strain of Shigella called Shigella flexneri 2a (or S. flexneri 2a) which is the most common type of Shigella that affects children living in the poorest countries. It was made by removing genes that normally allow Shigella to cause illness. Removing these genes is expected to weaken the vaccine to the point that it will only live for a few days in the intestine and will not cause diarrhea or fever. In addition, two ETEC genes were placed into the Shigella bacteria. One gene causes the Shigella bacteria to make tiny 'hairs' on its surface called 'colonization factor antigen type I', or 'CFA/I'. These 'hairs' are made of protein and help the ETEC stick to the intestine. The second gene causes the Shigella to make a protein called 'LTA2B'. LTA2B does not cause diarrhea, but it is part of the ETEC protein called 'heat labile toxin', or 'LT' which can cause watery diarrhea. CFA/I and LT are commonly found in ETEC that cause diarrhea. It is hoped that the CVD 1208S(pCFA/I-LTA2B) vaccine will protect people from future infections with S. flexneri 2a and with ETEC that make CFA/I and LT. The objectives of the study are as follows: + To evaluate the safety and clinical tolerability of a single dose of CVD 1208S(pCFA/I-LThA2B), with particular attention to the occurrence of diarrhea, dysentery, or fever; + To assess the immunogenicity of a single dose of CVD 1208S(pCFA/I-LThA2B) by measuring the responses that are most likely to be associated with protective immunity. + To evaluate the dose response of CVD 1208S(pCFA/I-LThA2B) so that a well-tolerated and immunogenic dosage level can be selected for further development; + To evaluate the extent and duration of shedding of CVD 1208S(pCFA/I-LThA2B); + To evaluate preliminarily the transmissibility of CVD 1208S(pCFA/I-LThA2B) by determining whether the vaccine strain is acquired by placebo recipients living in close proximity on the Research Isolation Ward, as identified by stool culture. Three groups of about 13 volunteers each will be admitted to the General Clinical Research Center Isolation Ward for 13-day period for Ward acclimatization, vaccination and observation. Volunteers in Group 1 will receive either CVD 1208S(pCFA/I-LTA2B) vaccine at a low dose of 10 million bacteria or placebo. If the dose appears to be safe, then Group 2 will be admitted to the GCRC and receive either CVD 1208S(pCFA/I-LTA2B) vaccine at a medium dose of 100 million bacteria or placebo. If the dose appears to be safe, then Group 3 will be admitted to the GCRC and receive either CVD 1208S(pCFA/I-LTA2B) vaccine at a high dose of 1 billion bacteria or placebo. After discharge from the inpatient portion of the study, each group will return to clinic for follow-up on Days 14, 21, 28 and 42 for stool check, a blood draw and safety check. Finally, six months following vaccination, volunteers will contacted via telephone for a safety check.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR016500-07
Application #
7718073
Study Section
Special Emphasis Panel (ZRR1-CR-3 (02))
Project Start
2008-03-01
Project End
2009-02-28
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
7
Fiscal Year
2008
Total Cost
$196,373
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Cedillo-Couvert, Esteban A; Ricardo, Ana C; Chen, Jinsong et al. (2018) Self-reported Medication Adherence and CKD Progression. Kidney Int Rep 3:645-651
Cedillo-Couvert, Esteban A; Hsu, Jesse Y; Ricardo, Ana C et al. (2018) Patient Experience with Primary Care Physician and Risk for Hospitalization in Hispanics with CKD. Clin J Am Soc Nephrol 13:1659-1667
Drawz, Paul E; Brown, Roland; De Nicola, Luca et al. (2018) Variations in 24-Hour BP Profiles in Cohorts of Patients with Kidney Disease around the World: The I-DARE Study. Clin J Am Soc Nephrol 13:1348-1357
Schrauben, Sarah J; Hsu, Jesse Y; Rosas, Sylvia E et al. (2018) CKD Self-management: Phenotypes and Associations With Clinical Outcomes. Am J Kidney Dis 72:360-370
Rahman, Mahboob; Hsu, Jesse Yenchih; Desai, Niraj et al. (2018) Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease. Clin J Am Soc Nephrol 13:585-595
Wrobleski, Margaret M; Parker, Elizabeth A; Hurley, Kristen M et al. (2018) Comparison of the HEI and HEI-2010 Diet Quality Measures in Association with Chronic Disease Risk among Low-Income, African American Urban Youth in Baltimore, Maryland. J Am Coll Nutr 37:201-208
Bundy, Joshua D; Bazzano, Lydia A; Xie, Dawei et al. (2018) Self-Reported Tobacco, Alcohol, and Illicit Drug Use and Progression of Chronic Kidney Disease. Clin J Am Soc Nephrol 13:993-1001
Bansal, Nisha; Xie, Dawei; Sha, Daohang et al. (2018) Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol 29:2859-2869
Harhay, Meera N; Xie, Dawei; Zhang, Xiaoming et al. (2018) Cognitive Impairment in Non-Dialysis-Dependent CKD and the Transition to Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 72:499-508
Bansal, Nisha; Roy, Jason; Chen, Hsiang-Yu et al. (2018) Evolution of Echocardiographic Measures of Cardiac Disease From CKD to ESRD and Risk of All-Cause Mortality: Findings From the CRIC Study. Am J Kidney Dis 72:390-399

Showing the most recent 10 out of 411 publications